Biotech News - Amazon Biotech, Inc. Announces Submitting of a Protocol to Test AMZ0026

Amazon Biotech, Inc. Announces Submitting of a Protocol to Test
AMZ0026 as an HIV Drug to Delay Onset of AIDS With the FDA

NEW YORK, April 18, 2006 -- Amazon Biotech, Inc. (OTCBB:AMZB) today
announced that it has filed a protocol to test AMZ0026 as an HIV
drug to delay onset of full-blown AIDS with the Food and Drug
Administration (FDA). The study is designed to include 60 non-
symptomatic HIV-infected subjects who have not been recently treated
with any AIDS medications. AMZ0026 versus placebo will be
administered for a 6 month treatment period, during which primary
endpoint parameters will be monitored, including "T" Cell increases
and the amount of HIV virus in the bloodstream. The drug formulation
is based upon the Amazon Biotech, Inc. philosophy of several active
ingredients working in combination, utilizing cutting edge whole
plant pharmaceutical drug technology to create a natural, healthier
pharmaceutical drug.

The new AMZ0026 HIV protocol is designed to evaluate this
investigational drug's ability to prevent the progression to AIDS in
HIV-infected individuals through assessment of AMZ0026's effect on
benchmark clinical markers for AIDS in this six month study.
Submission of a protocol with the FDA does not guarantee that the
FDA will approve the protocol, nor does it mean that there won't be
changes made in the protocol. Amazon Biotech is working closely with
the FDA, hoping to arrive at a protocol that will satisfy first and
foremost, all safety concerns and also show efficacy. Commitment to
do a study does not represent that the Company has FDA approval on
the Protocol to start the study.

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company,
primarily developing immune modulator drugs. AMZ 0026 is the
Company's first such drug, to be used for the treatment of HIV/AIDS.
The Company plans on initiating Phase I/II clinical studies of AMZ
0026 in the near future, with an eventual goal of attracting a joint
venture partner with a major pharmaceutical company in Phase III
trials, or follow the FDA Fast Track program to market. Amazon
Biotech specializes in natural plant pharmaceutical drugs and is
focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at:
http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation
Reform Act of 1995 This press release contains forward-looking
information within the meaning of Section 21E of the Securities
Exchange Act of 1934, including statements regarding any potential
sales of products as well as statements that include the
words "believes," "expects," "anticipates," or similar expressions.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of Amazon Biotech, to differ materially
from those implied or expressed by such forward-looking statements.
Such factors include, among others, the risk factors included in
Amazon Biotech's subsequent reports filed with the Securities and
Exchange Commission under the Exchange Act. This press release
speaks as of the date first set forth above and Amazon Biotech
assumes no responsibility to update the information included herein
for events occurring after the date hereof.

CONTACT: LC Group
Rick Lutz
(404) 261-1196

http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/